Rearrangement of the RET gene is detected by fluorescence in situ hybridization (FISH).
disease state indication(s)
Non-Small Cell Lung Cancer (NSCLC)
Predictive RET gene rearrangements are detected in 1-2% of NSCLC. The presence of RET gene rearrangement determines eligibility for targeted therapies (such as cabozantinib and vandetanib).
Fluorescence in situ hybridization (FISH)
specimen type and requirements
Preferred: One (1) or two (2) formalin-fixed, paraffin-embedded (FFPE) blocks containing tumor tissue from the most recent surgery or biopsy.
Acceptable Alternative: Two (2) to three (3) unstained FFPE tissue sections recently cut at 4 µm thickness on glass slides, plus accompanying H&E stained slide.
Unacceptable: Specimens preserved in alternative (non-formalin) fixatives, decalcified specimens, fresh or frozen tissue.
Note: Use refrigerated cold pack for transport. Make sure cold pack is not in direct contact with specimen.
DO NOT FREEZE.
Global (TC & PC): 7 days
medicare moldx cpt code
Laboratory developed test (LDT)
Global (TC & PC)